- Conditions
- Obstructive Sleep Apnea, Sleep-disordered Breathing
- Interventions
- Combination device and drug: Unilateral hypoglossal nerve stimulation & atomoxetine-plus-oxybutynin (HGNS+AtoOxy), Unilateral hypoglossal nerve stimulation (HGNS), active comparator condition, Atomoxetine-plus-oxybutynin (80/5 mg) (AtoOxy), active comparator condition, Placebo; placebo comparator condition
- Other · Device · Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–16
of 16
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Atomoxetine, Oxybutynin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy Volunteers
- Interventions
- Darifenacin, Oxybutynin, Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 150 participants
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Hyperhidrosis
- Interventions
- Oxybutynin 3% gel
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 12 Years to 25 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Overactive Bladder
- Interventions
- onaBoNT-A, Oxybutynin ER
- Drug
- Lead sponsor
- Christopher Patrick Smith
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Overactive Detrusor, Neurogenic Bladder
- Interventions
- Oxybutynin, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 3 Years to 16 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 10
- States / cities
- Loma Linda, California • Orange, California • Aurora, Colorado + 7 more
- Conditions
- Urinary Incontinence, Urge
- Interventions
- oxybutynin
- Drug
- Lead sponsor
- FemmePharma Global Healthcare, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Hackensack, New Jersey
- Conditions
- Overactive Bladder
- Interventions
- Omega 3 Fatty Acid, Placebo
- Drug
- Lead sponsor
- TriHealth Inc.
- Other
- Eligibility
- 18 Years to 85 Years · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Overactive Bladder
- Interventions
- trospium chloride, oxybutynin IR, oxybutynin IR placebo
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Spinal Cord Injuries, Urinary Bladder, Neurogenic
- Interventions
- Oxybutynin Chloride IR, Mirabegron
- Drug
- Lead sponsor
- Kessler Foundation
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- West Orange, New Jersey
- Conditions
- Diabetic; Neuropathic, Polyneuropathy (Manifestation)
- Interventions
- 3% oxybutynin, Placebo
- Drug
- Lead sponsor
- Eastern Virginia Medical School
- Other
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Healthy Volunteers
- Interventions
- oxybutynin chloride immediate-release, oxybutynin chloride topical gel, placebo
- Drug · Other
- Lead sponsor
- Watson Pharmaceuticals
- Industry
- Eligibility
- 60 Years to 79 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2008
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • National City, California • Maitland, Florida + 3 more
- Conditions
- Sleep Apnea
- Interventions
- Atomoxetine, Oxybutynin, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Memory, Cognition
- Interventions
- Tolterodine ER, Oxybutynin ER
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 65 Years to 75 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 9
- States / cities
- Tucson, Arizona • Brooksville, Florida • DeLand, Florida + 5 more
- Conditions
- Hot Flashes
- Interventions
- Fezolinetant, Paroxetine, Citalopram, Escitalopram, Desvenlafaxine, Venlafaxine, Gabapentin, Clonidine, Pregabalin, Oxybutynin, Any other SSRI/SNRI not already specified, Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 40 Years to 75 Years · Female only
- Enrollment
- 999 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Lomita, California + 39 more
- Conditions
- Urge Urinary Incontinence, Urinary Frequency
- Interventions
- Oxybutynin, Placebo
- Drug
- Lead sponsor
- Antares Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 626 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Laguna Hills, California + 50 more